 |
|
β-blockers in advanced cirrhosis: More friend than enemy
Ki Tae Yoon, Hongqun Liu, Samuel S. Lee
Clin Mol Hepatol. 2021;27(3):425-436. Published online 2020 Dec 3 DOI: https://doi.org/10.3350/cmh.2020.0234
|
|
Citations to this article as recorded by
 Cardiomyopathy in cirrhosis: From pathophysiology to clinical care
Hongqun Liu, Jwan A. Naser, Grace Lin, Samuel S. Lee
JHEP Reports.2024; 6(1): 100911. CrossRef Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension
Bert Vandenberk, Mario H. Altieri, Hongqun Liu, Satish R. Raj, Samuel S. Lee
Alimentary Pharmacology & Therapeutics.2023; 57(3): 290. CrossRef Non-invasive tests-based risk stratification: Baveno VII and beyond
Georg Semmler, Mathias Jachs, Mattias Mandorfer
Clinical and Molecular Hepatology.2023; 29(1): 105. CrossRef Correspondence on Editorial regarding “Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”
Yu Jun Wong, Sanchit Sharma, Giulia Tosetti, Xiaolong Qi, Massimo Primignani
Clinical and Molecular Hepatology.2023; 29(1): 188. CrossRef Potential therapies for acute‐on‐chronic liver failure
Maura A. Morrison, Florent Artru, Francesca M. Trovato, Evangelos Triantafyllou, Mark J. McPhail
Liver International.2023;[Epub] CrossRef Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus‐related liver cirrhosis
David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Nikolaos Pyrsopoulos, Seung Up Kim
Journal of Gastroenterology and Hepatology.2023; 38(8): 1372. CrossRef Dysregulated Calcium Handling in Cirrhotic Cardiomyopathy
Sang Youn Hwang, Hongqun Liu, Samuel S. Lee
Biomedicines.2023; 11(7): 1895. CrossRef How to suspect the presence of high‐risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia?
Ujjal Poddar, Arghya Samanta, Moinak Sen Sarma, Basant Kumar, Richa Lal, Anshu Srivastava, Vijay Datta Upadhyaya, Surender Kumar Yachha, Ankur Mandelia
Journal of Gastroenterology and Hepatology.2023; 38(9): 1610. CrossRef Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy
Hongqun Liu, Sang-Youn Hwang, Samuel S. Lee
Pharmaceuticals.2023; 16(7): 978. CrossRef Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
Xinyi He, Zimo Zhao, Xi Jiang, Yan Sun
Frontiers in Pharmacology.2023;[Epub] CrossRef Portal vein thrombosis in cirrhosis: exploring the uncharted waters
P Anirvan
Journal of Gastroenterology and Hepatology.2023; 38(10): 1855. CrossRef MicroRNAs as critical regulators in liver fibrosis
Xiaolin Wang, Qiuhong Zai, Yong He, Qing Xie
Portal Hypertension & Cirrhosis.2023; 2(3): 144. CrossRef The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status
Josip Stojic, Michał Kukla, Ivica Grgurevic
Diagnostics.2023; 13(18): 2960. CrossRef Nonselective beta-blockers may lead to stage 2 acute kidney injury and waitlist mortality in child class C cirrhosis
Mason Lai, Cynthia Fenton, Jin Ge, Jessica Rubin, Jennifer C. Lai, Giuseppe Cullaro
Hepatology Communications.2023;[Epub] CrossRef Hepatorenal syndrome: Current concepts and future perspectives
Chan-Young Jung, Jai Won Chang
Clinical and Molecular Hepatology.2023; 29(4): 891. CrossRef In severe alcohol‐related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL‐8 and micro‐RNAs
Luke D. Tyson, Stephen Atkinson, Robert W. Hunter, Michael Allison, Andrew Austin, James W. Dear, Ewan Forrest, Tong Liu, Emma Lord, Steven Masson, Joao Nunes, Paul Richardson, Stephen D. Ryder, Mark Wright, Mark Thursz, Nikhil Vergis
Alimentary Pharmacology & Therapeutics.2023; 58(11-12): 1217. CrossRef Gut liver brain axis in diseases: the implications for therapeutic interventions
Mengyao Yan, Shuli Man, Benyue Sun, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef Changes of the bacterial composition in duodenal fluid from patients with liver cirrhosis and molecular bacterascites
Jim Höppner, Sandra Krohn, Ellen H. A. van den Munckhof, René Kallies, Adam Herber, Katharina Zeller, Jan Tünnemann, Madlen Matz-Soja, Antonis Chatzinotas, Stephan Böhm, Albrecht Hoffmeister, Thomas Berg, Cornelius Engelmann
Scientific Reports.2023;[Epub] CrossRef Current knowledge about biomarkers of acute kidney injury in liver cirrhosis
Han Ah Lee, Yeon Seok Seo
Clinical and Molecular Hepatology.2022; 28(1): 31. CrossRef Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy
Hongqun Liu, Henry H. Nguyen, Ki Tae Yoon, Samuel S. Lee
Frontiers in Network Physiology.2022;[Epub] CrossRef Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database
Hankil Lee, Beom Kyung Kim
Journal of Gastroenterology and Hepatology.2022; 37(11): 2154. CrossRef Prolonged QT Interval in Cirrhosis: Twisting Time?
William Lee, Bert Vandenberk, Satish R. Raj, Samuel S. Lee
Gut and Liver.2022; 16(6): 849. CrossRef New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim
Clinical and Translational Gastroenterology.2022; 13(12): e00542. CrossRef Advances in cirrhotic cardiomyopathy
Hongqun Liu, Ki Tae Yoon, Jing Zhang, Samuel S. Lee
Current Opinion in Gastroenterology.2021; 37(3): 187. CrossRef
|